As reported in the Journal of Clinical Oncology by Gregory P. Kalemkerian, MD, and colleagues, ASCO has endorsed the College of American Pathologists (CAP), International Association for the Study of Lung Cancer (IASLC), and Association for Molecular Pathology (AMP) updated guideline on molecular testing for selection of lung cancer patients for targeted tyrosine kinase inhibitor treatment.
The endorsement was based on an ASCO expert panel review of the updated CAP/IASLC/AMP molecular testing guideline. The expert panel was co-chaired by Dr. Kalemkerian, of the University of Michigan, Ann Arbor, and Navneet Narula, MD, of Weill Cornell Medical College. ASCO endorsed the guideline with minor modifications. Key elements of the updated guideline are summarized below.
Key Elements
Additional information is available at www.asco.org/thoracic-cancer-guidelines and www.asco.org/guidelineswiki.
ASCO is the corresponding author for the Journal of Clinical Oncology article: e-mail: guidelines@asco.org.
The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.